The aberrant down-regulation of lncRNA GAS5 has been reported in breast cancer, renal cell carcinoma, bladder cancer, prostate cancer and pancreatic cancer22, 23, 26, 27, 28, 29, 30, however little is known regarding its expression in stomach cancer. Here, GAS5 is linked to breast carcinoma.